Key facts, as of
As of September 29, 2026, Bio-Techne Corporation (TECH) trades at $72.38, up 38.6% over the past year. It is at the top of its 52-week range ($43.20 to $72.69). It sits 17.0% above its 200-day average of $61.84, the usual sign of a long-term uptrend. Its 30-day volatility is 2.1% annualized, which we rate low risk. It has a trailing P/E of 62.4 and a dividend yield of 0.44%.
Cite: Portfolio Terminal, "Bio-Techne Corporation (TECH) stock analysis", 2026-09-29. https://portfolio-terminal.com/analyse/tech
Where it trades today
trading 99% of the way up its 52-week range
How the price has moved
What to weigh before acting
What Matters Now
- The read on the stock is often driven by pipeline durability, reimbursement pressure, and whether new launches can offset patent cliffs.
- TECH trades at 62.4x earnings, well above the healthcare average of 22.0x, so the market is already pricing in above-consensus execution.
- Recent realized volatility sits near 2.1%, below the sector norm of 22.0%, which supports a steadier role inside a diversified portfolio.
- Relative performance versus UNH, JNJ, PFE matters here because leadership inside healthcare rarely stays static for long.
Portfolio Use Case
- TECH is more useful for investors comparing conviction names inside healthcare than for someone looking for a passive “set and forget” holding.
- This name works better as a satellite or higher-conviction growth position because it can amplify market swings in both directions.
- The stock becomes more useful when paired with an explicit catalyst watchlist, because sector sentiment can shift quickly around policy, rates, or pipeline news.
What Would Change the View
- A reset in earnings expectations or a faster peer catch-up could compress the premium valuation currently embedded in TECH.
- The view would need revisiting if peers such as UNH, JNJ, PFE start winning the marginal flow or posting cleaner operating momentum.
Methodology
- Price, market cap, beta, yield, and liquidity fields for TECH come from Yahoo Finance quote and summary data.
- 30-day volatility is calculated from recent daily returns and annualized using a 252-trading-day convention.
- Sector context uses stored benchmark averages for Healthcare so each page compares the ticker against a stable peer baseline rather than against the whole market.
- Peer comparisons use the Portfolio Terminal coverage set and highlight nearby listed alternatives such as UNH, JNJ, PFE.
Sources
- Yahoo Finance quote dataopen →
Live quote, valuation, beta, yield, and volume fields used for TECH. Last refresh: Sep 29, 2026, 10:33 PM.
- Portfolio Terminal methodologyopen →
Explains how analytics, refresh cadence, and portfolio interpretation work across the product.
- Peer set and coverage context
Comparative context for this page is anchored around nearby tracked names such as UNH, JNJ, PFE.
What Bio-Techne Corporation does
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. It operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow…
What analysts expect
TECH is tracked by 11 analysts, with an average price target of $70.73 versus $72.38 today (-2.3%). Targets are estimates and can move quickly after earnings.
Consensus aggregated by Yahoo Finance. Targets are estimates, not forecasts.
How the business is doing
TECH generated $1.22B in trailing revenue (1.3% year over year), with a 15.0% net margin, and $229.65M of free cash flow, against $23.61M of net debt.
The numbers, year by year
| Fiscal year | Revenue | Gross profit | Operating income | Net income | EPS | Free cash flow |
|---|---|---|---|---|---|---|
| 2026 | $1.22B | $799.07M | $272.61M | $181.86M | $1.17 | $263.22M |
| 2025 | $1.22B | $790.27M | $242.80M | $73.40M | $0.47 | $256.55M |
| 2024 | $1.16B | $769.73M | $246.40M | $168.10M | $1.07 | $236.10M |
| 2023 | $1.14B | $769.82M | $291.00M | $285.26M | $1.81 | $216.15M |
When it reports next
Estimates aggregated by Yahoo Finance. Dates move and estimates change until the report lands.
How it sits in healthcare
Defensive sector including pharmaceuticals, biotech, medical devices, and healthcare services.
The companies it competes with
TECH beside the healthcare names it is usually measured against.
What the chart is saying
Trading at its high for the year, with no resistance overhead.
uptrend- Price is 0.2% above its 50-day average and 17.0% above its 200-day.
- The 50-day crossed above the 200-day on 2026-07-24 (a “golden cross”).
- RSI at 56 is neither stretched nor washed out.
- Nothing above has stopped it this year; the nearest floor is $70.55 (-2.5%).
A description of the chart, not advice. Indicators describe what the price has done; none of them knows what it does next.
Questions people ask about it
Is TECH a good buy right now?
Bio-Techne Corporation trades at 62.4x earnings. This is above market average, reflecting growth expectations. Current risk level is Low based on 2.1% volatility.
Does TECH pay dividends?
Yes, Bio-Techne Corporation offers a dividend yield of 0.44%. That is roughly $0.32 per share a year.
How volatile is TECH?
With 30-day annualized volatility of 2.1% and beta of 1.27, TECH is classified as Low risk. Expect larger swings than the broader market during volatile periods.
What is the analyst price target for TECH?
The average analyst price target for Bio-Techne Corporation (TECH) is $70.73 based on 11 analyst estimates, about 2.3% below the current price of $72.38. The published range runs from $50.00 to $73.00.
How much revenue does TECH generate?
Bio-Techne Corporation reported $1.22B in trailing twelve-month revenue. Revenue growth is running at 1.3% year over year. Net margin sits at 15.0%. Figures are aggregated from company filings by Yahoo Finance and refresh on an hourly cadence.
Compare TECH with anything
Five years side by side: what $10,000 became, how far each fell, whether they move together.